Denali Therapeutics Inc (FRA:4DN)
€ 20.31 -0.18 (-0.88%) Market Cap: 2.85 Bil Enterprise Value: 2.09 Bil PE Ratio: 0 PB Ratio: 2.25 GF Score: 54/100

Denali Therapeutics Inc at Wedbush PacGrow Healthcare Conference (Virtual) Transcript

Aug 10, 2021 - Aug 11, 2021 / NTS GMT
Release Date Price: €44.61 (+1.52%)
Laura Kathryn Chico
Wedbush Securities Inc., Research Division - SVP of Equity Research

Thanks, everybody, for joining us. My name is Laura Chico. I'm the senior biotech analyst here at Wedbush. So with our next panel, we will be discussing novel approaches in neuro. And I'm not only extremely excited about our speaker lineup today, but also a little awestruck by the collective years of experience that our panelists bring together here and confirming with everybody, it works out to be about 95 years of experience on our panel today. So pretty amazing.

Going around the Zoom room, though, we have Aptinyx CEO, Norbert Riedel; CEO of Denali Therapeutics, Ryan Watts; Sage Therapeutics CEO, Barry Greene; and Karuna Therapeutics CEO, Steve Paul. Gentlemen, thank you all to -- thanks to all of you for joining us today.

Just to set the stage, we are going to have each of our panelist start off by giving a brief introduction to themselves and their companies. I suspect everybody in the audience is probably already largely familiar with everybody, but we'll then transition to our panel

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot